Exactly opposite actually. Everyone likes a sale. Before this heads to the 20's, much buying will be performed by the shorts.
They said that on the REGN board back in 03 to 05.. They had to cover big time.. Another bio pharma that SNY partnered with. Too funny the many trolls that used to post over there. We know there little secret.
How is the interest rate coming on borrowing costs?
No worries here. One day this will be mid 50's. Bought more today. lol
2users liked this postsusers disliked this posts1Reply
old news from 2008: "Regeneron falls after downgrades by two analysts". And now we know that they we completely wrong about REGN
by biotech_invest • Jun 16, 2015 3:47 PM Flag
"Bloomberg reported Thursday that Regeneron shares dropped 20 percent, the most in five years, on the Nasdaq Stock Market after downgrades at Credit Suisse and Morgan Stanley.
Credit Suisse analyst Michael Aberman stopped recommending that investors buy the shares, citing "increased caution" about aflibercept. Recent data suggested the drug may have more toxic side effects than Genentech's Avastin. Analyst Aberman said that he is modifying probability adjusted net present value model and lowering his price target. The analyst expects REGN to be range bound in the high teens to low-$20s over the next 6-12 months, hence downgrading the stock.
Steven Harr of Morgan Stanley also abandoned his buy recommendation, however, both said investors should hold the stock.
Meanwhile, four other analysts still recommend buying Regeneron, whose largest shareholder is sanofi-aventis."
Currently, REGN is down $3.69 or 19.34% and trading at $15.39.
Controlled launch, insurance approvals, SNY internal infrastrure under pasale witz and dagmar kastellan(director of afrezza international expansion), clamp study label refinement to give first in it class treatment.. Google life science diabetes focus now on board having left out medtronic..
Nothing going on here. nope. And look at all the tools posting away...
I am looking for the google life sciences to replace the medtronics part of the deal. All redactions are removed. There is a short squeeze that will rival the VW one.. Longs are happy.. Jason, martin and adam are well... too bad..
Actually I saw a gal from an investment firm posting on twitter last night that was big on afrezza.